SCYNEXIS, Inc. is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.
The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development. Ibrexafungerp has been studied across multiple indications, including vulvovaginal candidiasis and invasive candidiasis, and has received regulatory designations such as Fast Track and Orphan Drug from the U.S. Food and Drug Administration. In addition to advancing its own pipeline, SCYNEXIS has established collaborations and received funding support from the Biomedical Advanced Research and Development Authority (BARDA) for development of ibrexafungerp as a potential countermeasure to emerging fungal threats.
Founded in 2007, SCYNEXIS completed its initial public offering in 2013 and has since focused on translating its preclinical discoveries into late‐stage clinical programs. Over the past decade, the company has expanded its clinical footprint with trials conducted in North America and Europe, while also building a regulatory and manufacturing foundation to support anticipated product launches.
SCYNEXIS is led by Chief Executive Officer Paul A. Rakestraw, who joined the company in 2019 and brings extensive experience in biopharmaceutical leadership and commercialization. The company’s executive team and board of directors combine expertise in infectious disease, regulatory affairs, and commercial strategy, positioning SCYNEXIS to address critical gaps in antifungal care around the world.
AI Generated. May Contain Errors.
